Skye Bioscience, Inc. (SKYE) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -8.56M | -9.77M | -13.36M | -10.75M | -9.19B | -8.17M | -5.26M | -7.09M | -4.71M | -3.84M | -4.05M | -1.99M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 99.91% | -19.5% | -153.94% | -51.49% | -194998.56% | -112.58% | -29.79% | -256.13% | -15.94% | 21.08% | -97.16% | 31.34% |
| Net Income | -12.51M | 11.08B | -12.75M | -17.62M | -11.1M | -9.75M | -3.9M | -7.9M | -5.02M | -4.42M | -24.95M | -3.11M |
| Depreciation & Amortization | 172.89K | -177.02M | 178.9K | 187.07K | 177.38K | 175.29K | 66K | 29.79K | 27.56K | 28.37K | 28.79K | 33.92K |
| Stock-Based Compensation | 0 | -2.2B | 1.91M | 2.03M | 2.2M | 2.09M | 1.92M | 1.83M | 2.48M | 592.85K | 160.21K | 102.87K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.5M | -8.72B | -91.4K | -89.36K | -9.18B | 178.32K | -4.44M | 507.12K | -907.94K | 64.56K | 21.29M | 30.33K |
| Working Capital Changes | 2.27M | 3.06M | -2.61M | 4.75M | -461.45K | -869.44K | 1.08M | -1.56M | -1.29M | -110.57K | -592.15K | 952.55K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.9M | -791.57K | -397.5K | 1.37M | 1.22M | -210.77K | -299.47K | -15.64K | -60.65K | -475.66K | -90.53K | 331.15K |
| Cash from Investing | 10.9M | -2.8M | 7.97M | -11.86M | -12.81B | 90.41K | -1.45M | -32.46K | 1.14M | -7.02K | 1.07M | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | -6.31M | -50.02K | -1.52M | -32.46K | -3.18K | -7.02K | -3.67K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 850 | 89.36K | 91.4K | 89.36K | 0 | -1.22M | 0 | 0 | 1.15M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 90.62K | 0 | 0 | 0 | 0 | 72.84K | 0 | 0 | 0 | 1.08M | 0 |
| Cash from Financing | -71.53K | 11.41K | 0 | 18.16K | 0 | 5.62K | 0 | -2.1M | 85.65M | -22.65K | 16.63M | -123.41K |
| Debt Issued (Net) | -71.53K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -22.65K | 4.9M | -123.41K |
| Equity Issued (Net) | 0 | 11.41K | 0 | 18.16K | 0 | -83.56M | 0 | -2.1M | 85.65M | 0 | 11.73M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 83.56M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.27M | -12.56M | -5.4M | -22.58M | -21.99B | -8.08M | -6.71M | -9.22M | 82.09M | -3.87M | 13.65M | -2.12M |
| Free Cash Flow | -8.56M | -9.77M | -13.36M | -10.75M | -9.19B | -8.22M | -6.78M | -7.13M | -4.71M | -3.85M | -4.06M | -1.99M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 99.91% | -18.77% | -97.08% | -50.8% | -195000.8% | -113.49% | -67.09% | -257.76% | -15.96% | 22.19% | -96.35% | 31.42% |
| FCF per Share | -0.22 | -0.25 | -0.34 | -0.27 | -231.81 | -0.21 | -0.17 | -0.18 | -0.17 | -0.31 | -0.51 | -0.51 |
| FCF Conversion (FCF/Net Income) | 0.68x | 0.68x | 1.05x | 0.61x | 827.27x | 0.84x | 1.35x | 0.90x | 0.94x | 0.87x | 0.16x | 0.64x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | -126.03K | 0 | 0 | 126.03K | 0 | 127.38K | 4.26K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | -2K | 0 | 0 | 2K | 0 | -5.14K | 3.6K |